Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose. Following administration, dabigatran plasma level rebounds have been reported but its consequ...
שמור ב:
| Principais autores: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2021-04-01
|
| סדרה: | Trauma Case Reports |
| נושאים: | |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S2352644021000273 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|